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Introduction
There is a substantial and growing
population of elderly adults (65 years and
older) who misuse alcohol, psychoactive
prescription drugs, and/or other substances
(Blow & Barry, 2016). Alcohol dependence and
alcohol abuse have now been combined into
one entity called Alcohol use disorder – AUD
(American Psychiatric Association, 2013).
This topic was chosen because studies have
shown that an average of 2.8 million adults
over the age of 50 suffered from substance use
disorders, including alcohol in the United
States. That number is projected to double,
totaling roughly 5.7 million seniors in five years
(Blow & Barry, 2016).
A variety of factors may contribute to AUD
in elderly (Blow & Barry 2016), they include:

Pathophysiological Processes
Underlying Pathophysiology
1. Mechanism of ETOH induced depression and the dopamine reward system
(Burchum & Rosenthal, 2019)
ETOH induces general depression and activation of the reward circuit via interaction with 1. Receptors
for gamma-aminobutyric acid (GABA) – the principal inhibitory neurotransmitter in the CNS. 2. Receptors
for glutamate – a major excitatory neurotransmitter in the CNS. 3. The 5-HT subset of receptors that mediate
the release of dopamine, the major neurotransmitter of the reward system.
When alcohol binds with GABA receptors, it enhances GABA-mediated inhibition thereby causing
widespread depression of CNS activity.
Whereas, when alcohol binds with N-methyl -D-aspartate (NMDA)-type of glutamate receptors, they
inhibit the flow of ions thereby blocking glutamate-mediated excitation and hence reduces the overall
activity of the CNS (Burchum & Rosenthal, 2019).
These pathophysiologic concepts explain why alcohol may be used by the elderly as an escape pathway
from the various problems associated with aging because it is a CNS depressant and it also feeds the reward
system.

2. Mechanism of alcohol metabolism in the liver

• Empty nest syndrome (when children grow
up and move away)

Figure 2. Alcohol metabolism in the liver.
Alcohol dehydrogenase (ADH); Cytochrome
Enzymes (P450 IIE1, CYP2E1); Aldehyde
dehydrogenase2 (ALDH2); Fatty acid ethyl ester
(FAEE); Acetaldehyde (CH3CHO); Hydrogen
peroxide (H2O2 ); Nicotinamide adenine
dinucleotide (NAD/NADH); Reactive oxygen
species (ROS). (Mandal et al., 2017).

• Loss of friendships due to moves, health
complications or death
• Deteriorating health conditions
(cardiovascular disease, vision/hearing loss,
and diabetes)
• Traumatic events like a spouse’s illness or
death
• Sadness after downsizing a home
• Boredom from retirement or lack of
socialization

Signs and Symptoms of
Alcohol Use Disorder
(AUD)

3. Epigenetic Mechanisms of Alcoholism
Figure 3. DNA methylation, histones
modifications, and folate deficiency. Acyl-CoA
synthetase 2 (ACSS2); ATP-citrate lyase (ACL);
S-adenosylmethionine (SAM); S-adenosyl
homocysteine (SAH); Histone methyl
transferase (HMT); Jumonji-C domaincontaining histone demethylases (JHDMs);
AMP-activated protein kinase (AMPK); Alcohol
dehydrogenase (ADH); Nicotinamide adenine
dinucleotide (NAD/NADH); Cytochrome
Enzymes (CYP2E1, P450 IIE1); Aldehyde
dehydrogenase (ALDH); CoA synthase (CoA-SH);
Lysine acetyltransferase (KAT); Sirtuin (SIRT);
Folic acid (FA); Tetrahydrofolate (THF);
Methylene tetrahydrofolate (MTHF);
Methionine synthase (MS); (MAT); Guanosine
diphosphate (GDP); Guanosine triphosphate
(GTP); Adenosine triphosphate (ATP);
Adenosine diphosphate (ADP); Adenosine
monophosphate (AMP). (Mandal et al., 2017).

4. Mechanism of ETOH induced liver disease
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Figure 1. Signs/Symptoms of AUD (Frazier
et al., 2011).

Figure 4. Inter-relationships among hepatic
steatosis, hepatitis, and Cirrhosis
(Medchrome, n.d.).

Significance of
Pathophysiology
Two neuropsychiatric syndromes are
exacerbated with AUD - Wernicke’s
encephalopathy and Korsakoff’s psychosis
(Burchum & Rosenthal, 2019).
Wernicke’s encephalopathy and
Korsakoff’s psychosis are caused by
thiamine deficiency secondarily to poor diet
and alcohol-induced suppression of
thiamine absorption.
Wernicke’s encephalopathy is
characterized by confusion, nystagmus, and
abnormal ocular movements. This
syndrome is reversible with thiamine.
Korsakoff’s psychosis is characterized
by polyneuropathy, inability to convert
short-term memory into long-term memory,
and confabulation. Korsakoff’s psychosis is
not reversible.
Long-term alcohol consumption leads to
cerebral atrophy and enlargement of the
ventricles. It is associated with impairment
of memory and intellectual function
(Burchum & Rosenthal, 2019).
The acetate that is a by-product of ETOH
metabolism is used to synthesized
cholesterol and fatty acids by the liver. That
explains why excessive alcohol
consumption can lead to the alcoholinduced fatty liver which can progress to
non-viral hepatitis and cirrhosis
AUD can lead to DNA hypomethylation,
histones acetylation, methylation,
phosphorylation, ubiquitination, and
crotonylation. Taken together, these events
can lead to gene silencing, and a prelude to
ETOH induced liver diseases, and
hepatocellular carcinoma.

Diagnosis
Several screening tools are available to
make AUD diagnosis. (Berks & McCormick
2018; Rumpf et al., 2016).
Alcohol Use Disorders Identification
Test (AUDIT) is used to assess whether or
not there is a problem with alcohol
dependence.
Severity of Alcohol Dependence
Questionnaire (SADQ) is used where
alcohol dependence has been identified,
and to measure the severity of dependence.
The revised Clinical Institute
Withdrawal Assessment for Alcohol scale
assessment (CIWA-Ar) is used to assess the
severity of alcohol withdrawal syndrome.
General medical workup should include
Vital signs, CBC, BMP, LFTs; it should be
done to rule out any medical problems.

Treatment

Conclusion

The best outcome as supported by evidence is combining psychosocial treatments with
medications.
Psychosocial treatments include brief interventions, motivational enhancement therapy, cognitivebehavioral therapy, behavioral approaches, family therapies, and 12-step facilitation (Pearson & Duff
2019).
Medications include Food and Drug Administration (FDA) approved and non-FDA approved
medications. There are only four FDA approved medications to treatment AUD ( Kranzler & Soyka
2018), and they are as follow
1. Disulfiram inhibits aldehyde dehydrogenase, an enzyme that metabolizes acetaldehyde, a toxic
metabolite of alcohol. Inhibiting the enzyme rapidly increases the concentration of acetaldehyde and
produces a disulfiram-ethanol reaction (DER) characterized by nausea, flushing, vomiting, sweating,
hypotension, palpitations, and rarely, serious reactions including cardiovascular collapse ( Kranzler &
Soyka 2018)
2. Naltrexone is a non-selective antagonist of mu, kappa, and delta-opioid receptors which was
initially approved to treat opioid dependence. It reduces mesolimbic opioidergic activity thereby
modulating the dopamine-mediated rewarding effects of alcohol; it reduces alcohol consumption (
Kranzler & Soyka 2018)
3. Acamprosate modulates glutamatergic neurotransmission, which explains its efficacy in treating
AUD ( Kranzler & Soyka 2018)
4. Long-acting injectable Naltrexone is used to treat alcohol dependence in patients who can
abstain from alcohol in an outpatient setting ( Kranzler & Soyka 2018)
Non-FDA-approved medications for treating AUD are often used off-label. Typical representatives
are Nalmefene, Baclofen, gabapentin, and Topiramate ( Kranzler & Soyka 2018)

There are several reasons why AUD
can lead to negative outcomes for the
elderly:
Changes in body composition with
aging result in higher blood alcohol
concentrations for a given alcohol
intake (Shenvi et al., 2020).
Older adults tend to have more
chronic medical conditions, take more
prescription medications
(polypharmacy), and are at higher risk
of falls, all of which can be complicated
or worsened by high‐risk alcohol use
(Shenvi et al., 2020).
Symptoms of excess alcohol use,
such as gait disturbances, falls, or
confusion may be interpreted as signs
of aging or other conditions (Shenvi et
al., 2020).
Chronic use of alcohol produces
physical dependence, and abrupt
withdrawal produces abstinence
symptoms that may include
hallucinations, intense tremors, tonicclonic seizures, elevated heart rate,
blood pressure, and temperature
(Burchum & Rosenthal 2019).
Individuals who have a physical
alcohol dependence have crossdependence to other CNS depressants
such as barbiturate, benzodiazepines.
Chronic alcohol consumption
produces tolerance – requirement for
larger amount of alcohol to produce the
same effects. They also develop crosstolerance to general anesthetics,
barbiturates, and other CNS
depressants (Burchum, J. R., Rosenthal,
L. D., 2019).

Implications for Nursing Care
RNs should be aware that elderly people who have AUD are significant for the following:
• Ineffective coping that may be related to the stress of bereavement
• Impaired adaptive behavior and problem-solving skills
• Self-neglect related to alcohol misuse
• Risk for malnutrition-related to alcohol misuse
• Risk for injury related to alcohol abuse

Nursing Interventions
• Explore alternative coping strategies such as the use of relaxation skills, and guided imagery (Stuart,
2019). Rationale - Patient may have little or no knowledge of adaptive responses to stress and needs
to learn other options for managing time, feelings, and relationships without drugs. Alternative
coping strategies will help patient to relax, develop new ways to deal with stress, and problemsolving
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• Encourage verbalization of feelings, fears, and anxiety (Stuart, 2019). Rationale - This may help the
patient to begin to come to terms with long-unresolved issues.
• Encourage involvement with self-help associations (Alcoholics Anonymous) (Stuart, 2019). Rationale
- Alcoholics Anonymous will put the patient in direct contact with the support system necessary for
managing sobriety and live an alcohol-free life.
• Use peer support to find ways of spending time on interesting life leisure (Townsend & Morgan,
2017). Rationale - Understanding and support from his peer group will help to promote abstinence
• Discuss with the patient the long-term effect of excessive alcohol use including Wernicke’s
encephalopathy and Korsakoff’s psychosis (Townsend & Morgan, 2017).
• Discuss treatment referral where he will have the opportunity to be managed with medications that
will diminish the crave for alcohol (Townsend & Morgan, 2017).
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